The patent expiration of several blockbuster biologic drugs has opened the floodgates for the development of highly competitive biosimilar products globally. This shift has altered the economics of the pharmaceutical industry, putting a strong premium on cost-effective, high-yield manufacturing processes. To stay competitive, biosimilar developers must optimize every aspect of their upstream...
Bangla